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ABSTRACT
Background: Localized mast cell accumulation has been reported in a number of human diseases. Suplatast
tosilate has been reported to inhibit IL-3-dependent murine mast cell development, and therefore is expected to
suppress mast cell growth proliferation at disease sites. However, there are differences between the growth
factors required by human and mouse mast cells．
Methods: Human mast cells were grown in serum-free culture condition from cord blood mononuclear cells
with suplatast tosilate. Mast cell number was assessed from the cell numbers counted by a flow cytometer with
constant flow rate and Kit+ percentage. Immunochemistry for tryptase was also examined on the cytocentri-
fuged preparations．
Results: Suplatast tosilate (100 μgml ) dramatically inhibited human mast cell development from cord blood
progenitors. On the other hand, the growth of 8-wk old mast cells that developed in serum-free media, and
which reached over 95% in purity and still maintained proliferation ability, and the growth of the human mast
cell line HMC-1 cells were not inhibited by suplatast tosilate．
Conclusions: Suplatast tosilate may be useful for control of human mast cell numbers at the local sites by in-
hibiting their development from their progenitors．
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INTRODUCTION
Suplatast tosilate (IPD-1151T) inhibits the formation
of IgE by reducing interleukin ( IL- ) 4 production
from T cells without having a direct effect on B cells,
and it is now recognized as a new type of anti-allergy
drug.1-5 This agent specifically inhibits the production
of T helper 2 (Th2) cytokines, and suppresses local
eosinophilia regulated by Th 2 cells . In addition ,
suplatast tosilate inhibits in vitro differentiation of
murine mast cells from normal splenocytes in the
presence of IL-3.6
However , there are considerable differences be-
tween murine and human mast cells including the
factors required for development and growth. Human
mast cells differentiate under the influence of stem
cell factor (SCF),7-9 and IL-3 has little, if any, influ-
ence on the differentiation of human mast cells other
than to expand the pool of hematopoietic progenitors,
in contrast to rodent mast cells.10 Therefore the sup-
pressive effect of suplatast tosilate on induction of
mast cell differentiation from progenitor cells must be
evaluated with human samples. Here, we report that
suplatast tosilate inhibited the differentiation of hu-
man mast cells from cord blood progenitors.
METHODS
AGENT
Suplatast tosilate was kindly supplied as a powder by
Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). The
powder was dissolved in saline , filtered through a
0.45 μm filter, and added to the cultures at the time of
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cell seeding and then once a week when the medium
was replaced.
HUMAN MAST CELL CULTURE
Serum-free culture of human mast cells was per-
formed as reported before with slight modifica-
tions.11-13 Briefly, cord blood was obtained at normal
full-term delivery with informed consent. All subjects
of this study provided written informed consent, and
the procedures were approved by the Human Studies
Internal Review Board of Kyoto University (#322) .
Mononuclear cells were separated by density-
gradient centrifugation and were cultured with 100
ngml recombinant human SCF ( rhSCF ; Amgen ,
Thousand Oaks , CA, USA) and 50 ngmL rhIL-6
(Kirin Brewery Co., Ltd., Gunma, Japan) in serum-
free AIM-V medium (Invitrogen, Carlsbad, CA, USA).
Half of the culture medium was replaced once a week
with fresh medium containing the same amount of
rhSCF without rhIL-6．
HMC-1, a human mast cell line, kindly provided by
Dr. Y. Kitamura (Osaka University, Osaka, Japan),
was cultured in α-MEM containing 10% fetal calf se-
rum (FCS)．
FLOW CYTOMETRY
The number of cultured cells was counted with a
FACS Vantage flow cytometer (BD Immunocytome-
try Systems, San Jose, CA, USA) for 20 sec at a con-
stant flow rate, as described previously.14
For detection of surface Kit expression, cells were
first incubated in phosphate-buffered saline (PBS)
containing normal goat serum for 30 min at 4℃． Af-
ter washing in PBS containing 1% FCS and 0.1% so-
dium azide, the cells were incubated with a phyco-
erythrin (PE) -conjugated anti-Kit monoclonal anti-
body (mAb)(YB5.B8 ; BD Pharmingen, San Jose, CA,
USA). After washing, the cells were analyzed with the
flow cytometer. Propidium iodide staining was done
to exclude dead cells．
IMMUNOCYTOCHEMISTRY
Tryptase expression was examined by indirect im-
munocytochemical staining . 14 Briefly , cytocentri-
fuged preparations were fixed in methanol for 30 min,
washed, blocked with normal horse serum in PBS,
and incubated overnight at 4℃ with anti-tryptase
mAb G3 (Chemicon International , Temecula , CA,
USA). After washing, the cells were incubated for 30
min at 20℃ with alkaline phosphatase-conjugated
horse anti-mouse IgG ( Vector Laboratory , Burl-
ingame, CA, USA), and reaction products were visual-
ized with naphthol AS-BInew fuchsin (positive cells
were stained red) . The cells were lightly counter-
stained with hematoxylin．
STATISTICAL ANALYSIS
The significance of differences between the control
and experimental group was assessed using Student’
s t -test．
RESULTS
SUPPRESSION OF HUMAN MAST CELL DIFFER-
ENTIATION FROM CORD BLOOD BY
SUPLATAST TOSILATE
Suplatast tosilate was added at a concentration of 100
μgml at the time of seeding mononuclear cells from
cord blood, because this concentration was used pre-
viously . 6 The results of four separate experiments
were comparable. The appearance under an inverted
microscope after 2 weeks is shown in Figure 1A.
Suplatast tosilate dramatically suppressed cell
growth. Moreover most of the surviving cells in the
cultures containing suplatast tosilate were tightly ad-
herent to the bottom of the culture wells, and were
larger than most of the cells from cultures without
suplatast tosilate . A few of these tightly adherent
cells, probably of non-mast cell linage, were also ob-
served in the control well among the round cells, as
shown by white arrowheads in Figure 1A. Immunocy-
tochemistry for tryptase on cytocentrifuged prepara-
tions of the cells made after 2 weeks of culture
showed that the percentage of tryptase+ cells was de-
creased from 59.5 ± 7.8% (n = 4, mean ± SD) without
suplatast tosilate to 9.4 ± 6.2 (n = 4) with suplatast to-
silate (Fig. 1B). The percentage of cells exhibiting
metachromasia on toluidine blue staining was almost
the same as the tryptase+ cells under each set of cul-
ture conditions (data not shown)．
Next, we added 1, 10, and 100 μgml of suplatast
tosilate at the initiation of mononuclear cell culture.
Flow cytometric analysis of the cultured cells after 2
weeks revealed two distinct subpopulations (Fig. 2A).
We previously reported that the population of smaller
and less granular cells represented cells undergoing
apoptosis,14 so counted the cells in R1 as viable cells.
Suplatast tosilate reduced R1 cells in a concentration
dependent manner, and cell numbers were dramati-
cally decreased at a concentration of 100 μgml. In
detail, the number of R1 cells was as follows : 1,217 ±
196 cells20 sec without suplatast tosilate (n = 4,
mean ± SD), 1,048 ± 46 cells20 sec at 1 μgml (n =
4),864 ± 76 cells20 sec at 10 μgml (n = 4), and 240
± 84 cells20 sec at 100 μgml (n = 4). As shown in
Figure 2B, the percentage of Kit+ among the viable
cells was also decreased, being 54.0 ± 1.7% (n = 4,
mean ± SD) without suplatast tosilate, 51.2 ± 1.7% (n =
4) at 1 μgml, 51.7 ± 1.6% (n = 4) at 10 μgml, and
28.2 ± 2.5% (n = 4) at 100 μgml. The overall decrease
of surviving cells and decrease of Kit+ cells during
culture with suplatast tosilate resulted in a
concentration-dependent decrease of mast cell num-
bers. At concentrations of 10 and 100 μgml, the dif-
ference in mast cell numbers was significant com-
pared to that in cultures without the reagent (p < 0.01,
Fig. 2C).
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Fig. 1 Diferentiation of human mast cels from cord blood 
was suppressed by suplatast tosilate (IPD). A: After culture 
for 2 weeks in the presence or absence of suplatast tosilate 
(views obtained with an inverted microscope). White arow-
heads in the control panel show strongly adherent non-mast 
cels.  In the presence of 100 μg/ml of suplatast tosilate, 
most of the surviving cels were such adherent cels.  Origi-
nal magnification ×100. B:  Immunocytochemistry for tryp-
tase on cytocentrifuged preparations of 2-week cultured 
cels.  Black arows show tryptase-positive cels.  Original 
magnification ×200.
A
B
Control IPD 100 µg/ml
Fig. 2　Flow cytometric analysis shows suppression of hu-
man mast cel diferentiation from cord blood by suplatast to-
silate (IPD).  A: Forward (FSC) and side (SSC) scater 
reveal two distinct subpopulations. The R1 gate was set on 
viable cels. B: Kit expression. Cels in the M1 region were 
counted as positive.  C:  Mast cel numbers after culture for 
2-weeks were calculated from the total number of viable 
cels in R1 and the percentage of Kit+ cels (n=4). **p<0.01 
by Student’ st-test.
Control IPD 100 µg ml
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INFLUENCE OF SUPLATAST TOSILATE ON HU-
MAN MAST CELL GROWTH
According to the data of Konno et al. who examined
the effect of suplatast tosilate on murine mast cells,6 it
is expected to inhibit the growth of mast cell progeni-
tors but not that of mature mast cells. Serum-free cul-
ture permits earlier, more selective, and greater ex-
pansion of human mast cells than serum-containing
culture.12-14 Thus, mast cells cultured for 8 weeks in
serum-free medium showed over 95% purity, and re-
tained proliferative activity, so a culture seeded at a
concentration of 1 × 106 cellswell increased to 1.82 ±
0.22 × 106 cellswell (n = 4, mean ± SD) in a 24-well
culture plate after 1 week. Under these culture condi-
tions with rhSCF, addition of any dose of suplatast to-
silate for another 1 week did not suppress mast cell
growth (Fig. 3A), indicating that even 100 μgml of
suplatast tosilate showed no toxicity for differentiated
mast cells.
In our serum-free culture of cord blood progeni-
tors, rhIL-6 is only added in during the first week for
expansion of total cell numbers. To examine whether
the suppression of mast cell differentiation from cord
blood progenitors by suplatast tosilate was mediated
through IL-6 signaling pathways , 8-week cultured
cells were also incubated with the reagent in medium
containing rhSCF and rhIL-6. After 1 week of culture,
however, there was no difference of cell numbers in
the presence or absence of suplatast tosilate (data not
shown)．
We also checked the effect of the suplatast tosilate
on HMC-1 cells, which are often used as a model of
immature human mast cells, because they lack high
affinity IgE receptors and contain few granules. The
growth of HMC-1 cells was rapid, with numbers ex-
panding from 0.5 × 106 cellswell to 4.02 ± 0.32 × 106
cellswell after 3 days of culture (n = 4). When the ef-
fect of suplatast tosilate was assessed after 3 days at
concentrations of 1, 10 and 100 μgml, none of these
doses could inhibit HMC-1 cell growth (Fig. 3B).
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Fig. 3 Efect of suplatast tosilate (IPD) on mature human 
mast cels and HMC-1 cels.  A:  Number of 8-weeks cul-
tured mast cels after another 1 week of culture with rhSCF 
in the presence or absence of suplatast tosilate (n=4).  B:  
Number of HMC-1 cels after 3 days of culture in the pres-
ence or absence of suplatast tosilate (n=4). 
A
B
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
%
 g
ro
w
th
%
 g
ro
w
th
0 1 10 100
IPD (µg/mL)
0 1 10 100
IPD (µg/mL)
120.0
100.0
80.0
60.0
40.0
20.0
0.0
DISCUSSION
In a number of human diseases, such as asthma,15,16
allergic rhinitis,17,18 rheumatoid arthritis,19 and atopic
dermatitis with lichenification,20-22 a significant local
increase of mast cells has been reported and mast
cells are thought to play a central role in the patho-
physiology of inflammation associated with these con-
ditions. We recently reported that human mast cells
are capable of proliferating while retaining several
key phenotypic features, which could contribute to
tissue mast cell hyperplasia.23 However, expansion of
mast cells at specific sites in the tissues has generally
been thought to occur when more of the pool of he-
matopoietic progenitor cells is diverted to a mast cell
lineage, or by stimulating the proliferation of mast
cell progenitors, as well as by increasing the recruit-
ment of mast cells and their precursors to the tissues
or by lengthening the survival of mast cells.
Suplatast tosilate is a new type of anti-allergy drug
that inhibits production of Th2 cytokines. It was re-
ported to inhibit IL-3-dependent differentiation of
murine mast cells from splenocytes , 6 and was
thought to be a good candidate anti-allergy drug that
would inhibit the induction of mast cell differentia-
tion. However, there are differences between murine
and human mast cell, especially with respect to the
factors required for differentiation and growth . 10
Therefore , we evaluated the suppressive effect of
suplatast tosilate on the differentiation of human mast
cells from cord blood progenitors.
The present study revealed that suplatast tosilate
inhibited SCF-dependent human mast cell differentia-
tion. We also confirmed that it exerted an inhibitory
action on mast cell progenitors but not on mature
mast cells . In cultures of human progenitors in
serum-free medium, mainly mast cells are supported
by SCF, and many cells of non-mast cell lineages, die
as shown by the population of cells located outside R1
in Figure 2 (which were smaller and less granular
than the cells in R1). Therefore, it is difficult to evalu-
ate cytotoxicity when culturing cells from progeni-
tors, so there remains the possibility that suplatast to-
silate shows specific toxicity for mast cell progeni-
tors. However, suplatast tosilate did not show toxicity
for cells of non-mast cell lineage or for differentiated
mast cells and HMC-1 cells . The mechanisms by
which suplatast tosilate inhibited mast cell differentia-
tion remains unclear. Because it showed no inhibi-
tory effect on 8-week cultured mature human mast
cells, the signaling pathway involving SCF and its re-
ceptor (Kit) may have no relevance to this action of
the drug. A contribution of signaling via IL-6 is also
unlikely, because the growth of 8-week cultured hu-
man mast cells with both SCF and IL-6 was not af-
fected by suplatast tosilate. Even though SCF is the
only growth factor reported to support the in vitro
growth and differentiation of human mast cells by it-
self ,7-9,12,24 unknown factors produced by accessory
cells in the early period of culture or known factors
that acts in ways we still do not understand may affect
mast cell growth, especially in the early stage of in-
duction, and suplatast tosilate may act on such fac-
tors.
In conclusion, suplatast tosilate inhibited the differ-
entiation of human mast cells from cord blood pro-
genitors . This agent may be useful for controlling
mast cell numbers at sites of inflammation by inhibit-
ing development from progenitors. However, there is
no evidence yet as to whether suplatast tosilate can
have the same effect in vivo, especially at clinical
doses which produce a maximum blood level of 43.2
± 9.1 ngml at 2.8 ± 1.3 h after the oral administra-
tion.25
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